

Noam C. Diamant BIOS

Noam is an experienced biopharma professional with a deep scientific background. Prior to NOGA Therapeutics, Noam co-founded Emendo Biotherapeutics, a leading genome editing company that was acquired by Angenics, Japan in 2020 for \$295M. As an expert in intellectual property strategy, Noam has advised dozens of biomed companies, building their patents portfolios. Noam holds a PhD from the Weizmann Institute in the field of DNA damage repair.